Nonalcoholic fatty liver disease and non-liver comorbidities

키워드

참고문헌 (113)

1. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean nonalcoholic fatty liver disease : a systematic review and metaanalysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
2. Zou B, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016", J Intern Med, 288, pp.139~151 (2020)
3. Li J, "Meta-analysis : global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021", Aliment Pharmacol Ther, 56, pp.396~406 (2022)
4. Yu EL, "Prevalence of nonalcoholic fatty liver disease in children with obesity", J Pediatr, 207, pp.64~70 (2019)
5. Newton KP, "Incidence of type 2 diabetes in children with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol (2022)[DOI]
6. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
7. Paik JM, "Changes in the global burden of chronic liver diseases from 2012 to 2017 : the growing impact of NAFLD", Hepatology, 72, pp.1605~1616 (2020)
8. Golabi P, "Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa : Data from Global Burden of Disease 2009-2019", J Hepatol, 75, pp.795~809 (2021)
9. Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : A systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
10. Golabi P, "Mortality of NAFLD according to the body composition and presence of metabolic abnormalities", Hepatol Commun, 4, pp.1136~1148 (2020)
11. Loomba R, "Mechanisms and disease consequences of nonalcoholic fatty liver disease", Cell, 184, pp.2537~2564 (2021)
12. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
13. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
14. Kleiner DE, "Association of histologic disease activity with progression of nonalcoholic fatty liver disease", JAMA Netw Open, 2, pp.e1912565~ (2019)
15. Reddy YK, "Natural history of non-alcoholic fatty liver disease : a study with paired liver biopsies", J Clin Exp Hepatol, 10, pp.245~254 (2020)
16. Wong VW, "Disease progression of non-alcoholic fatty liver disease : a prospective study with paired liver biopsies at 3 years", Gut, 59, pp.969~974 (2010)
17. McPherson S, "Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies : implications for prognosis and clinical management", J Hepatol, 62, pp.1148~1155 (2015)
18. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
19. Adams LA, "The histological course of nonalcoholic fatty liver disease : a longitudinal study of 103 patients with sequential liver biopsies", J Hepatol, 42, pp.132~138 (2005)
20. Park J, "NASH", Liver fibrosis prevalence and incidence of nonliver comorbidities among people with NAFLD and incidence of NAFLD by metabolic comorbidities : lessons from South Korea, 2021, pp.39, 634~645
21. Targher G, "NAFLD and increased risk of cardiovascular disease : clinical associations, pathophysiological mechanisms and pharmacological implications", Gut, 69, pp.1691~1705 (2020)
22. Targher G, "Nonalcoholic fatty liver disease and risk of incident cardiovascular disease : A meta-analysis", J Hepatol, 65, pp.589~600 (2016)
23. Kasper P, "NAFLD and cardiovascular diseases : a clinical review", Clin Res Cardiol, 110, pp.921~937 (2021)
24. Oni E, "Life’s simple 7 and nonalcoholic fatty liver disease : the multiethnic study of atherosclerosis", Am J Med, 134, pp.519~525 (2021)
25. Plaz Torres MC, "Mediterranean diet and NAFLD : what we know and questions that still need to be answered", Nutrients, 11, pp.2971~ (2019)
26. Lloyd-Jones DM, "Life’s essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association", Circulation, 146, pp.e18~e43 (2022)
27. Younossi ZM, "The impact of fatigue on mortality of patients with nonalcoholic fatty liver disease : Data from National Health and nutrition examination survey 2005-2010 and 2017-2018", Liver Int, 42, pp.2646~2661 (2022)
28. Lazarus JV, "Defining comprehensive models of care for NAFLD", Nat Rev Gastroenterol Hepatol, 18, pp.717~729 (2021)
29. Kanwal F, "Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease", Gastroenterology, 161, pp.1657~1669 (2021)
30. Wong VWS, "Management of NAFLD in primary care settings", Liver Int, 42, pp.2377~2389 (2022)
31. Cusi K, "American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings : co-sponsored by the American Association for the Study of Liver Diseases(AASLD)", Endocr Pract, 28, pp.528~562 (2022)
32. Younossi ZM, "Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices", Aliment Pharmacol Ther, 52, pp.513~526 (2020)
33. Srivastava A, "Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease", J Hepatol, 71, pp.371~378 (2019)
34. Long MT, "AGA clinical practice update : diagnosis and management of nonalcoholic fatty liver disease in lean individuals : expert review", Gastroenterology, 163, pp.764~774 (2022)
35. Younossi ZM, "AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease : expert review", Gastroenterology, 160, pp.912~918 (2021)
36. Simon TG, "Non-alcoholic fatty liver disease and incident major adverse cardiovascular events : results from a nationwide histology cohort", Gut, 71, pp.1867~1875 (2022)
37. Perseghin G, "Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver", Hepatology, 47, pp.51~58 (2008)
38. Rijzewijk LJ, "Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus", J Am Coll Cardiol, 52, pp.1793~1799 (2008)
39. Trovato FM, "Echocardiography and NAFLD(non-alcoholic fatty liver disease)", Int J Cardiol, 221, pp.275~279 (2016)
40. Zhang Z, "Chronic heart failure in patients with nonalcoholic fatty liver disease : prevalence, clinical features, and relevance", J Int Med Res, 46, pp.3959~3969 (2018)
41. Valbusa F, "Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure", Int J Cardiol, 265, pp.162~168 (2018)
42. Mantovani A, "Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease", Metabolism, 64, pp.879~887 (2015)
43. Bonapace S, "Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus", PLoS One, 9, pp.e88371~ (2014)
44. Wen X, "Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease(NAFLD)or Nonalcoholic Steatohepatitis(NASH)", PLoS One, 16, pp.e0251665~ (2021)
45. Moshayedi H, "Association between non-alcoholic fatty liver disease and ischemic stroke", Iran J Neurol, 13, pp.144~148 (2014)
46. Tziomalos K, "Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome", World J Hepatol, 5, pp.621~626 (2013)
47. Ansel Shao Pin Tang, "Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals", Clinical and Molecular Hepatology, 28(3), pp.483~496 (2022), 대한간학회[DOI]
48. Kim SU, "Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke", Atherosclerosis, 260, pp.156~162 (2017)
49. Hu J, "Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease : a meta-analysis", Oncotarget, 9, pp.2752~2760 (2017)
50. Mori T, "Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke", Hepatol Int, 16, pp.81~88 (2022)
51. Wu M, "Non-alcoholic fatty liver disease and stroke : A Mendelian randomization study", Eur J Neurol, 29, pp.1534~1537 (2022)
52. Li H, "Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions", Eur J Neurol, 25, pp.577~ (2018)
53. Käräjämäki AJ, "Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population(OPERA Study)", PLoS One, 10, pp.e0142937~ (2015)
54. Mantovani A, "Nonalcoholic fatty liver disease(NAFLD)and risk of cardiac arrhythmias : a new aspect of the liver-heart axis", J Clin Transl Hepatol, 5, pp.134~141 (2017)
55. Chen Z, "Nonalcoholic fatty liver disease : an emerging driver of cardiac arrhythmia", Circ Res, 128, pp.1747~1765 (2021)
56. Straus SM, "Prolonged QTc interval and risk of sudden cardiac death in a population of older adults", J Am Coll Cardiol, 47, pp.362~367 (2006)
57. Hung CS, "Nonalcoholic fatty liver disease is associated with QT prolongation in the general population", J Am Heart Assoc, 4, pp.e001820~ (2015)
58. Mantovani A, "Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease", Dig Dis Sci, 61, pp.1246~1267 (2016)
59. Mantovani A, "Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring", Diabetes Care, 39, pp.1416~1423 (2016)
60. Shahab O, "Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality", Hepatol Commun, 2, pp.1227~1234 (2018)
61. Harrison SA, "Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
62. Harrison SA, "A 52-week phase 3 clinical trial of resmetirom in 180 patients with well-compensated NASH cirrhosis", Hepatology, 76, pp.S90~S92 (2022)
63. Dongiovanni P, "PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients", J Lipid Res, 60, pp.1144~1153 (2019)
64. Kawashiri MA, "Can PCSK7 be a new pharmaceutical target?", J Atheroscler Thromb, 29, pp.1265~1267 (2022)
65. Mantovani A, "Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease : A systematic review and metaanalysis", Metabolism, 79, pp.64~76 (2018)
66. Ciardullo S, "Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD : a systematic review and meta-analysis", Biomolecules, 12, pp.105~ (2022)
67. Ahmed MH, "Obstructive sleep apnea syndrome and fatty liver : association or causal link?", World J Gastroenterol, 16, pp.4243~4252 (2010)
68. Chin K, "Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients", Am J Med, 114, pp.370~376 (2003)
69. Koo SH, "Nonalcoholic fatty liver disease : molecular mechanisms for the hepatic steatosis", Clin Mol Hepatol, 19, pp.210~215 (2013)
70. Tilg H, "NAFLD and diabetes mellitus", Nat Rev Gastroenterol Hepatol, 14, pp.32~42 (2017)
71. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
72. Vassilatou E, "Nonalcoholic fatty liver disease and polycystic ovary syndrome", World J Gastroenterol, 20, pp.8351~8363 (2014)
73. Paschou SA, "Nonalcoholic fatty liver disease in women with polycystic ovary syndrome", Endocrine, 67, pp.1~8 (2020)
74. Kim JJ, "Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 45, pp.1403~1412 (2017)
75. Liu SH, "Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women : results from NHANES III", J Gastroenterol, 48, pp.1151~1159 (2013)
76. Yang JD, "Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 15, pp.127~131 (2017)
77. Frøssing S, "Effect of liraglutide on ectopic fat in polycystic ovary syndrome : A randomized clinical trial", Diabetes Obes Metab, 20, pp.215~218 (2018)
78. Sinha RA, "Direct effects of thyroid hormones on hepatic lipid metabolism", Nat Rev Endocrinol, 14, pp.259~269 (2018)
79. Liangpunsakul S, "Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?", J Clin Gastroenterol, 37, pp.340~343 (2003)
80. Pagadala MR, "Prevalence of hypothyroidism in nonalcoholic fatty liver disease", Dig Dis Sci, 57, pp.528~534 (2012)
81. Kim D, "Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis", Clin Gastroenterol Hepatol, 16, pp.123~131 (2018)
82. Hassan MM, "Association between hypothyroidism and hepatocellular carcinoma : a case-control study in the United States", Hepatology, 49, pp.1563~1570 (2009)
83. Tanase DM, "Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease(HIN) : mechanisms and emerging therapeutic options", Int J Mol Sci, 21, pp.5927~ (2020)
84. Takano S, "Effect of growth hormone on fatty liver in panhypopituitarism", Arch Dis Child, 76, pp.537~538 (1997)
85. Hazem A, "Body composition and quality of life in adults treated with GH therapy : a systematic review and meta-analysis", Eur J Endocrinol, 166, pp.13~20 (2012)
86. Pan CS, "Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease", Clin Endocrinol(Oxf), 94, pp.183~192 (2021)
87. Allen AM, "The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity-A longitudinal cohort study", J Hepatol, 71, pp.1229~1236 (2019)
88. Liu SS, "Association between nonalcoholic fatty liver disease and extrahepatic cancers : a systematic review and meta-analysis", Lipids Health Dis, 19, pp.118~ (2020)
89. Wong VW, "High prevalence of colorectal neoplasm in patients with nonalcoholic steatohepatitis", Gut, 60, pp.829~836 (2011)
90. Mantovani A, "Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers : a meta-analysis of observational cohort studies", Gut, 71, pp.778~788 (2022)
91. Ning L, "Association between Helicobacter pylori infection and nonalcoholic fatty liver disease : a systemic review and meta-analysis", Eur J Gastroenterol Hepatol, 31, pp.735~742 (2019)
92. Abdel-Razik A, "Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma?", Helicobacter, 23, pp.e12537~ (2018)
93. Boursier J, "The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota", Hepatology, 63, pp.764~775 (2016)
94. Sachdeva S, "NAFLD and COVID-19 : a pooled analysis", SN Compr Clin Med, 2, pp.2726~2729 (2020)
95. Ji D, "Non-alcoholic fatty liver diseases in patients with COVID-19 : A retrospective study", J Hepatol, 73, pp.451~453 (2020)
96. Adenote A, "NAFLD and infection, a nuanced relationship", Can J Gastroenterol Hepatol, 2021, pp.5556354~ (2021)
97. Younossi ZM, "Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 17, pp.2552~2560 (2019)
98. Younossi ZM, "Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis : the impact on patient-reported outcomes", Hepatol Commun, 4, pp.1637~1650 (2020)
99. Younossi ZM, "The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis", Gastroenterology, 160, pp.1608~1619 (2021)
100. Weinstein AA, "Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C", Psychosomatics, 52, pp.127~132 (2011)
101. Zou B, "A nationwide study of inpatient admissions, mortality, and costs for patients with cirrhosis from 2005 to 2015 in the USA", Dig Dis Sci, 65, pp.1520~1528 (2020)
102. Nguyen AL, "Rising inpatient encounters and economic burden for patients with nonalcoholic fatty liver disease in the USA", Dig Dis Sci, 64, pp.698~707 (2019)
103. Younossi ZM, "Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease", J Clin Gastroenterol, 49, pp.222~227 (2015)
104. Sayiner M, "Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis", J Clin Gastroenterol, 51, pp.254~260 (2017)
105. Gordon SC, "Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis medicare patients", Am J Gastroenterol, 115, pp.562~574 (2020)
106. Romero-Gomez M, "Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease", nonalcoholic steatohepatitis(NAFLD, Medicine(Baltimore), pp.2020, 99[DOI]
107. Petta S, "Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy", Nutr Metab Cardiovasc Dis, 30, pp.1014~1022 (2020)
108. "J Hepatol", 2018, S32~
109. Hagström H, "Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls", Clin Gastroenterol Hepatol, 18, pp.1592~1599 (2020)
110. Younossi ZM, "The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe", Hepatology, 64, pp.1577~1586 (2016)
111. Younossi ZM, "Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States", Hepatology, 69, pp.564~572 (2019)
112. Tampi RP, "Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia : Data from Hong Kong", Hepatol Res, 50, pp.1024~1031 (2020)
113. Papić N, "Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection", Eur J Clin Microbiol Infect Dis, 39, pp.569~574 (2020)

관련 논문AI추천